Theravance Biopharma Deal Faces Investor Probe

·15 Aug
Share:PostShare

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's board fulfilled its fiduciary duties. Theravance maintains that the deal offers significant value, representing a premium over its stock price before the acquisition announcement.

S

STL.News

Original source

Read full story

Related Stories

Bitcoin and Ether bears get decimated amid 'squeeze-led' rally and Musk's X wants to pay creators in stablecoins: Crypto's week in 5 stories

Bitcoin and Ether bears get decimated amid 'squeeze-led' rally and Musk's X wants to pay creators in stablecoins: Crypto's week in 5 stories CoinDesk Why bitcoin prices are suddenly rallying big-time Yahoo Finance Bitcoin jumps further on U.S. crypto policy hopes CP24 Bitcoin and gold surge as Bessent's bond market intervention weighs on dollar Financial Post Gold and Bitcoin Are Rallying as Debasement Chatter Picks Up Bloomberg.com

GGoogle News

Banks, fintechs, NPCI: Who gets what when MDR returns to UPI

Banks, fintechs, NPCI: Who gets what when MDR returns to UPI Moneycontrol.com Keeping UPI accessible, secure and trusted: Balancing free payments with systemic growth Deccan Herald Selective UPI MDR Will Need Reliable Merchant Intelligence, Not Just a Pricing Rule TheWire.in Keep UPI free, and fund it from the savings it generates The Indian Express MDR on UPI transactions worth ₹2,000 & above likely in 2 weeks: Report | Zero MDR was introduced in January 2020 | Inshorts Inshorts

GGoogle News

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer